There is an unmet clinical need for genomicsbased precision medicine approaches that can identify therapeutic targets and effective therapeutic regimens for individual patients with pancreatic ductal adenocarcinoma (PDAC). In the first of three related studies, Heining, Horak, Uhrig, and colleagues identified NRG1 rearrangements that may be targeted with ERBB inhibitors in young patients with KRAS wildtype PDAC. In the second study, Aguirre, Nowak, Camarda, and colleagues used a rapid biopsy protocol to characterize the genomic landscape of 71 PDACs and identify potentially targetable alterations. Finally, Tiriac and colleagues performed genomic, transcriptomic, and therapeutic profiling of PDAC patientderived organoids, identifying expression signatures that predict response to chemotherapy. Altogether, these studies provide insights that may facilitate precision medicine in patients with PDAC. For details, please see the articles by Heining, Horak, Uhrig, and colleagues on page 1087, Aguirre, Nowak, Camarda, and colleagues on page 1096, and Tiriac and colleagues on page 1112.